Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Carisma Therapeutics Inc CARM

Healthcare Biotechnology
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing its proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. It is developing a pipeline of product candidates, with an initial focus on advancing multiple ex vivo autologous and in vivo CAR-M therapies for the... see more

Recent & Breaking News (NDAQ:CARM)

Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference

PR Newswire May 6, 2024

Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer

PR Newswire May 2, 2024

Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

PR Newswire April 24, 2024

Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

PR Newswire April 22, 2024

Carisma Therapeutics to Present at Upcoming Conferences

PR Newswire April 3, 2024

Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

PR Newswire April 1, 2024

Carisma Therapeutics Announces Changes to its Board of Directors

PR Newswire April 1, 2024

Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

PR Newswire March 21, 2024

Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference

PR Newswire February 28, 2024

Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

PR Newswire December 21, 2023

First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration

PR Newswire December 14, 2023

Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte

PR Newswire November 28, 2023

Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference

PR Newswire November 22, 2023

Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

PR Newswire November 9, 2023

Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC

PR Newswire October 31, 2023

Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023

PR Newswire October 25, 2023

Carisma Therapeutics to Present at Upcoming Investor Conferences

PR Newswire September 5, 2023

Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit

PR Newswire September 1, 2023

Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023

PR Newswire August 24, 2023

Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

PR Newswire August 10, 2023